These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 32387678)

  • 1. Advances in genome editing for genetic hearing loss.
    Ding N; Lee S; Lieber-Kotz M; Yang J; Gao X
    Adv Drug Deliv Rev; 2021 Jan; 168():118-133. PubMed ID: 32387678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene editing based hearing impairment research and therapeutics.
    Kang W; Sun Z; Zhao X; Wang X; Tao Y; Wu H
    Neurosci Lett; 2019 Sep; 709():134326. PubMed ID: 31195050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.
    Farooq R; Hussain K; Tariq M; Farooq A; Mustafa M
    J Appl Genet; 2020 Feb; 61(1):51-65. PubMed ID: 31912450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
    Liu W; Yang C; Liu Y; Jiang G
    Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome Editing: The Recent History and Perspective in Cardiovascular Diseases.
    Musunuru K
    J Am Coll Cardiol; 2017 Dec; 70(22):2808-2821. PubMed ID: 29191331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
    Wan T; Ping Y
    Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic applications of CRISPR RNA-guided genome editing.
    Koo T; Kim JS
    Brief Funct Genomics; 2017 Jan; 16(1):38-45. PubMed ID: 27562951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
    Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
    Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in therapeutic application of CRISPR-Cas9.
    Sun J; Wang J; Zheng D; Hu X
    Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses.
    Gilani U; Shaukat M; Rasheed A; Shahid M; Tasneem F; Arshad M; Rashid N; Shahzad N
    J Med Virol; 2019 Jan; 91(1):1-13. PubMed ID: 30133783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Creating cell and animal models of human disease by genome editing using CRISPR/Cas9.
    Zarei A; Razban V; Hosseini SE; Tabei SMB
    J Gene Med; 2019 Apr; 21(4):e3082. PubMed ID: 30786106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.